A certificate of analysis looks reassuring because it speaks in numbers. There is a batch number, a laboratory name, perhaps a chromatogram, and a purity percentage close to one hundred. The page appears to turn a complicated quality question into a simple score.
It does something narrower. A certificate records specified results for a sample or batch, using specified methods. Its value depends on what was tested, how the sample relates to the material in question, and whether the methods and records deserve confidence. It cannot answer a question that the testing never addressed.
Reading that boundary correctly is more useful than being impressed by an extra decimal place.
Start with what the percentage measures
“Purity” needs a definition. NIST’s archived report for peptide reference material RM 8327, for example, distinguished ultraviolet absorbance area purity from peptide mass purity. The former concerned relative analytical signals; the latter concerned the mass of peptide within the material. It also reported molecular-mass measurements separately. This old reference document illustrates a lasting measurement principle: different reported quantities are not interchangeable. NIST’s peptide reference-material report
An area percentage from a chromatographic method therefore should not automatically be read as the percentage of the entire sample’s mass that is the intended peptide. Nor should a large peak be asked to establish every other property of a product. The meaning comes from the method and the quantity it measures, not the word “purity” in isolation.
Identity is another question. Does the evidence distinguish the intended compound from plausible alternatives? Amount is another: how much of the relevant substance is present? A report may address several questions, but one favorable result cannot silently stand in for the others.
FDA’s analytical-validation guidance treats identification, assay, and impurity testing as purposes requiring suitable evidence. It discusses specificity or selectivity, accuracy, precision, and the range over which a method works. In ordinary language, a measurement needs to detect the right thing reliably under the conditions in which it is used. An impressive-looking graph does not demonstrate that on its own. FDA’s Q2(R2) analytical-validation guidance
A report needs a traceable subject
A result is only as relevant as its connection to the material being discussed. A generic certificate with an unrelated batch number cannot establish the properties of a different batch. A document about an ingredient does not automatically describe the finished product after further processing, packaging, transport, and storage.
FDA’s Q7 guidance for active pharmaceutical ingredients provides a useful benchmark for documentation. It describes certificates that identify the material and batch, state the tests, acceptance limits and numerical results where applicable, and identify the original manufacturer and authorized quality personnel. It also addresses certificates issued through repackers or brokers. These are recommendations within a pharmaceutical quality framework, not a promise that any document with similar formatting meets that framework. FDA’s Q7 guidance, section 11.4
This is why “third-party tested” leaves important questions unanswered. Which sample did the laboratory receive? What did it test? Who connects that sample to the final material? A laboratory’s existence and a batch’s history are separate matters. Even an authentic laboratory result has a defined scope.
Chemical quality and microbiological quality are different
A chemically identified peptide may still require assessment for microbial contamination and bacterial endotoxins. These are not alternative names for a chemical purity result. U.S. finished-drug manufacturing regulations explicitly require appropriate testing for batches represented as sterile or pyrogen-free. A chromatogram alone does not fulfill those distinct questions. 21 CFR 211.167
Endotoxins are associated with Gram-negative bacteria, and eliminating viable microorganisms does not necessarily eliminate their endotoxins. FDA’s technical discussion describes this distinction, including instances of sterile devices contaminated with endotoxins. “Sterile” and “free of clinically relevant endotoxin contamination” therefore cannot simply be substituted for one another. FDA’s explanation of bacterial endotoxins and pyrogens
Even an endotoxin result needs an appropriate method. FDA’s guidance revised in March 2026 discusses product-related interference and the need to justify test methods and limits. The meaningful question is whether suitable testing supports the particular product specification, not whether the document contains the word “endotoxin.” FDA’s current pyrogen and endotoxin guidance
None of this creates a home checklist that can qualify an unknown injectable product for use. A collection of uploaded reports does not let a reader reconstruct a controlled manufacturing process or establish the condition of every finished container.
Quality evidence does not establish clinical benefit
There is a final leap that no analytical certificate can make: from identifying a substance to showing that taking it improves health. A clinical claim requires evidence about people, the intended use, the relevant outcomes, and harms. Those questions remain even if the analytical work is excellent.
Regulatory status remains separate too. FDA explains that compounded drugs are not FDA-approved and do not undergo the agency’s premarket review for safety, effectiveness, or quality. A certificate does not supply that review. FDA’s explanation of compounded-drug risks
A useful way to read a certificate is to complete a precise sentence: this report supports this measured property, for this identified material, under these stated conditions. If the next sentence claims universal safety, clinical effectiveness, or regulatory approval, it needs a different kind of evidence. The number on the first page cannot do all that work.
A thought worth keeping?
